2023-08-02

Q Chiranjeevi Kondapaka, as the representative of Steriline Asia, can you tell us about the recent announcement regarding Steriline Asia Pvt. Ltd. and its significance for Steriline's presence in the Indian pharmaceutical industry?

Chiranjeevi Kondapaka: Present customers are appreciating more direct relationships with the manufacturer over agents. With Steriline Asia, we are at customers’ doorstep. We are just arm’s length away. It gives more confidence and helps in developing trust with Asian customers.

Q What specific factors led to the decision of Steriline and INCOME to collaborate and form Steriline Asia? How do both companies aim to leverage their strengths to enhance their presence in the Indian market? 

Chiranjeevi Kondapaka: Steriline is well known for its advanced technology and INCOME has the expertise to offer the best service at affordable cost, leading to greater customer satisfaction in PAN India market. Thus, India evolved as one of the key markets for Steriline and Steriline became the main contributor to INCOME growth. Thus, the formation of Steriline Asia is inevitable.

The unique combination of a strong customer support system along with the latest technology in the field of Artificial Intelligence and the latest Analytical tools, like IoT, and vision-based inspection systems are the need of the current times. I am sure Steriline Asia has better opportunities to leverage their technology.

Q Federico Fumagalli, as the Chief Commercial Officer at Steriline, could you provide us with an overview of the strategic advantages and benefits that Steriline Asia brings to the Indian pharmaceutical industry?

Federico Fumagalli: Establishing an office in India can offer several strategic advantages and benefits to the pharmaceutical industry in the Country.

India is one of the world's fastest-growing pharmaceutical markets, with rising demand for healthcare products and services. Steriline, setting up an office in India, allows pharmaceutical companies to have a direct connection to the headquarters.

Having Steriline a physical presence in India provides our customers with an interface which is in the same understanding and can react promptly to their requests.

Q Filippo Parini, as the Sales Area Manager at Steriline, could you highlight the key products, solutions, or technologies that Steriline Asia will offer to the Indian pharmaceutical industry? How do you believe these offerings will address the industry's needs and contribute to its growth?

Filippo Parini: Steriline is currently offering two different kinds of products:

· Robotic filling lines

· Traditional filling lines

The above two technologies are different but complementary.

Robotic machines address all the issues related to small batch production, such as flexibility, reduced format changes, and product loss minimization.

Traditional machines are indicated when higher speed and big batch production are required.

Steriline, with its complete portfolio, can address all the fill&finish equipment requests, ranging from personalized medicines and CDMO productions (potent and not-potent), to generics productions.

Steriline is also expert in containment systems, hence it is the perfect partner in the aseptic filling field, whenever a turn-key solution is required.

Having its headquarter in Italy, and now a Subsidiary in India, Steriline is now even more efficient and closer to Indian partners.

Q What are some of the challenges or opportunities Steriline Asia anticipates in the Indian market? How does the company plan to overcome challenges and capitalize on opportunities to establish a strong presence? 

Chiranjeevi Kondapaka: Indian market is already filled with strong domestic competition. However, the know-how part of technology is still missing from these suppliers. Probably, this is the key opportunity for us to encash. I believe Steriline is the only European company offering complete end-to-end solutions with the latest robotic technology. Perhaps, Steriline would be the best fit to owner-driven organisations, where offerings are value for money. Technology & performance are assured.

Q Chiranjeevi Kondapaka, could you shed some light on the long-term vision and growth plans of Steriline Asia? What are the company's aspirations for its role in the Indian pharmaceutical industry?

Chiranjeevi Kondapaka: We shall be starting immediately with the designing of the spares, machine assemblies to leverage from the local talent pool, extending service support to the global market, creating a 24x7 software supporting system, etc. Eventually, we are open to produce machines.

Q With the establishment of Steriline Asia, how do you foresee the overall landscape of the Indian pharmaceutical industry evolving? What impact do you expect Steriline Asia to have on the industry's standards and practices? 

Chiranjeevi Kondapaka: Steriline Asia will certainly add a significant impact on the Indian Pharmaceutical industry. It offers belongingness, Steriline is much closer than in the past, the decisions are quick and the support system is more GLOCALISED (Global technology with Local intelligence). It improves the quality of the local supplier and improves India’s market share in the regulatory market with improved standards, Asian countries get more access to regulatory markets.